

Clemens Kratochwil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7819887/publications.pdf>

Version: 2024-02-01

120
papers

14,179
citations

23500

58
h-index

20900

115
g-index

131
all docs

131
docs citations

131
times ranked

6458
citing authors

#	ARTICLE	IF	CITATIONS
1	⁶⁸ Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 801-805.	2.8	874
2	The diagnostic value of PET/CT imaging with the ⁶⁸ Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 197-209.	3.3	866
3	²²⁵ Ac-PSMA-617 for PSMA-Targeted α -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1941-1944.	2.8	741
4	German Multicenter Study Investigating ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 85-90.	2.8	646
5	Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1415-1422.	2.8	522
6	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷ Lu-Labeled PSMA-617. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1170-1176.	2.8	475
7	⁶⁸ Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. <i>Journal of Nuclear Medicine</i> , 2019, 60, 386-392.	2.8	468
8	A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1423-1429.	2.8	453
9	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 914-920.	2.8	451
10	Diagnostic performance of ⁶⁸ Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1258-1268.	3.3	425
11	Targeted α -Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵ Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1624-1631.	2.8	367
12	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1697-1705.	2.8	332
13	Targeted α -Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵ Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. <i>Journal of Nuclear Medicine</i> , 2018, 59, 795-802.	2.8	322
14	Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1421-1429.	2.8	281
15	EANM procedure guidelines for radionuclide therapy with ¹⁷⁷ Lu-labelled PSMA-ligands (¹⁷⁷ Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	3.3	265
16	An Overview of Targeted Alpha Therapy with ²²⁵ Actinium and ²¹³ Bismuth. <i>Current Radiopharmaceuticals</i> , 2018, 11, 200-208.	0.3	248
17	Dosimetry for ¹⁷⁷ Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 42-51.	3.3	244
18	Detection Efficacy of ¹⁸ F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 362-368.	2.8	238

#	ARTICLE	IF	CITATIONS
19	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 79S-89S.	2.8	200
20	⁶⁸ Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 34-41.	3.3	194
21	Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: ⁶⁴ Cu- and ²²⁵ Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. <i>Journal of Nuclear Medicine</i> , 2020, 61, 563-569.	2.8	176
22	FAPI-74 PET/CT Using Either ¹⁸ F-ALF or Cold-Kit ⁶⁸ Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, 201-207.	2.8	163
23	¹⁷⁷ Lu-PSMA Radioligand Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1196-1200.	2.8	159
24	[¹⁷⁷ Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 987-988.	3.3	155
25	Radiation dosimetry of ⁶⁸ Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1611-1620.	3.3	143
26	Targeted Alpha Therapy, an Emerging Class of Cancer Agents. <i>JAMA Oncology</i> , 2018, 4, 1765.	3.4	143
27	Intra-individual Comparison of ¹⁸ F-PSMA-1007 and ¹⁸ F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1076-1080.	2.8	140
28	Targeting of activated fibroblasts for imaging and therapy. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 16.	1.8	134
29	Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving ²²⁵ Ac-PSMA-617 Radioligand Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 62-69.	2.8	128
30	Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. <i>European Urology</i> , 2021, 79, 343-350.	0.9	128
31	Intra-individual comparison of ¹⁸ F-FET and ¹⁸ F-DOPA in PET imaging of recurrent brain tumors. <i>Neuro-Oncology</i> , 2014, 16, 434-440.	0.6	120
32	Nomograms to predict outcomes after ¹⁷⁷ Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	5.1	120
33	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2045-2054.	3.3	116
34	Head-to-head intra-individual comparison of biodistribution and tumor uptake of ⁶⁸ Ga-FAPI and ¹⁸ F-FDG PET/CT in cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4377-4385.	3.3	114
35	Impact of ⁶⁸ Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas. <i>Journal of Nuclear Medicine</i> , 2021, 62, 779-786.	2.8	113
36	Design and Development of ^{99m} Tc-Labeled FAPI Tracers for SPECT Imaging and ¹⁸⁸ Re Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1507-1513.	2.8	110

#	ARTICLE	IF	CITATIONS
37	Targeted alpha therapy of mCRPC: Dosimetry estimate of ²¹³ Bismuth-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 31-37.	3.3	107
38	The Role of ⁶⁸ Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1331-1336.	2.8	106
39	⁶⁸ Ga or ¹⁸ F for Prostate Cancer Imaging?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 687-688.	2.8	105
40	PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 293-298.	2.8	100
41	Intraindividual Comparison of ¹⁸ F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1805-1810.	2.8	91
42	⁶⁸ Ga-FAPI-PET/CT in patients with various gynecological malignancies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4089-4100.	3.3	91
43	¹⁸ F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1929-1930.	3.3	81
44	⁶⁸ Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1943-1948.	2.8	81
45	Fibroblast activation protein targeted therapy using [¹⁷⁷ Lu]FAPI-46 compared with [²²⁵ Ac]FAPI-46 in a pancreatic cancer model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 871-880.	3.3	80
46	Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. <i>Endocrine-Related Cancer</i> , 2011, 18, 595-602.	1.6	79
47	²²⁵ Ac-PSMA-617 for Therapy of Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 133-140.	2.5	78
48	Development and dosimetry of ²⁰³ Pb/ ²¹² Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1081-1091.	3.3	77
49	Diagnostic Accuracy of ¹⁸ F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2021, 62, 208-213.	2.8	77
50	Intraindividual Comparison of Selective Arterial versus Venous ⁶⁸ Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 2899-2905.	3.2	76
51	Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 405-418.	2.5	72
52	Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing ²²⁵ Ac-PSMA-617 RLT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 139-147.	3.3	72
53	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [¹⁷⁷ Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 113-122.	3.3	72
54	Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 127-133.	2.8	72

#	ARTICLE	IF	CITATIONS
55	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with ¹³¹ I-MIP-1095. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 950-959.	3.3	69
56	Repeated ¹⁷⁷ Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. <i>Journal of Nuclear Medicine</i> , 2018, 59, 459-465.	2.8	68
57	FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?. <i>Cancers</i> , 2021, 13, 4946.	1.7	67
58	Comparison of ⁶⁸ Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. <i>Neuro-Oncology</i> , 2015, 17, 312-319.	0.6	64
59	Patients Resistant Against PSMA-Targeting α -Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 683-688.	2.8	61
60	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeutics. <i>Theranostics</i> , 2016, 6, 1085-1095.	4.6	60
61	[¹⁵³ Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3011-3013.	3.3	60
62	FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1754-1755.	3.3	58
63	Biochemical Recurrence of Prostate Cancer: Initial Results with [¹⁸ F]PSMA-1007 PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 632-635.	2.8	55
64	Radionuclide Therapy of Metastatic Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 313-325.	2.5	54
65	The Future of Radioligand Therapy: α , β , or Both?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1017-1018.	2.8	53
66	⁶⁸ Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 234-240.	2.8	49
67	¹⁸ F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e497-e499.	0.9	47
68	Correlation Between SUV _{max} and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 282-287.	2.8	44
69	Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2040-2041.	3.3	42
70	Tumor Sink Effect in ⁶⁸ Ga-PSMA-11 PET: Myth or Reality?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 226-232.	2.8	42
71	⁶⁸ Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation. <i>Radiotherapy and Oncology</i> , 2021, 160, 192-201.	0.3	40
72	Response Prediction of ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. <i>Journal of Nuclear Medicine</i> , 2020, 61, 689-695.	2.8	39

#	ARTICLE	IF	CITATIONS
73	18F-labeled tracers targeting fibroblast activation protein. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 26.	1.8	38
74	Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 54-63.	3.3	35
75	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e7-729.e16.	0.8	34
76	Multimodal Imaging for Early Functional Response Assessment of 90Y-/177Lu-DOTATOC Peptide Receptor Targeted Radiotherapy with DW-MRI and 68Ga-DOTATOC-PET/CT. <i>Molecular Imaging and Biology</i> , 2014, 16, 586-594.	1.3	32
77	Simultaneous whole-body 18Fâ€“PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 340-347.	3.3	32
78	Intraindividual Comparison of ^{99m} Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^{99m} Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1373-1379.	2.8	31
79	Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients. <i>Molecular Imaging and Biology</i> , 2017, 19, 315-322.	1.3	30
80	⁶⁸ Ga-DOTA-GGNle-CycMSH _{hex} targets the melanocortin-1 receptor for melanoma imaging. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	30
81	Two Tumors, One Target. <i>Clinical Nuclear Medicine</i> , 2021, 46, 842-844.	0.7	30
82	Radioligands Targeting Fibroblast Activation Protein (FAP). <i>Cancers</i> , 2021, 13, 5744.	1.7	30
83	PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 268-281.	2.5	29
84	FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. <i>European Journal of Radiology</i> , 2020, 127, 109021.	1.2	28
85	⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1949-1955.	2.8	27
86	Dosimetry Estimate and Initial Clinical Experience with ⁹⁰ Y-PSMA-617. <i>Journal of Nuclear Medicine</i> , 2019, 60, 806-811.	2.8	27
87	Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. <i>Journal of Nuclear Medicine</i> , 2020, 61, 46-50.	2.8	26
88	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 143-151.	3.3	25
89	Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 70-79.	2.8	23
90	Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to 68Ga-DOTATOC PET. <i>European Journal of Radiology</i> , 2015, 84, 1593-1600.	1.2	21

#	ARTICLE	IF	CITATIONS
91	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. <i>Oncotarget</i> , 2019, 10, 17-29.	0.8	21
92	The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4067-4076.	3.3	20
93	Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 168-180.	0.4	19
94	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	2.0	19
95	First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 311-312.	3.3	18
96	Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2059-2061.	3.3	18
97	The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging. <i>PET Clinics</i> , 2021, 16, 341-351.	1.5	18
98	Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. <i>Annals of Nuclear Medicine</i> , 2022, 36, 293-301.	1.2	13
99	DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. <i>Mutagenesis</i> , 2019, 34, 239-244.	1.0	12
100	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer – Results from a prospective pilot study using a 37 gene panel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 637.e17-637.e27.	0.8	12
101	Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 344-344.	0.8	11
102	Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients. <i>Cancer Imaging</i> , 2017, 17, 30.	1.2	8
103	Predicting the Risk of Metastases by PSMA-PET/CT – Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma. <i>Cancers</i> , 2021, 13, 1508.	1.7	8
104	Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2761-2769.	1.2	7
105	Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC. <i>Diagnostic and Interventional Radiology</i> , 2016, 22, 201-206.	0.7	6
106	Future trends in prostate cancer theranostics with PSMA ligands. <i>Clinical and Translational Imaging</i> , 2016, 4, 487-489.	1.1	6
107	Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 79-82.	0.9	6
108	Role of CT Density in PET/CT-Based Assessment of Lymphoma. <i>Molecular Imaging and Biology</i> , 2018, 20, 641-649.	1.3	6

#	ARTICLE	IF	CITATIONS
109	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. Journal of Clinical Oncology, 2022, 40, 5043-5043.	0.8	5
110	A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model. Molecular Imaging and Biology, 2016, 18, 243-248.	1.3	4
111	[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. Clinical Genitourinary Cancer, 2018, 16, 111-113.	0.9	4
112	Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, 103-105.	0.9	4
113	Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis. Molecular Imaging and Biology, 2018, 20, 1044-1052.	1.3	3
114	Positive Multifocal PSMA PET/CT in a Patient With Prostate Cancer and Follicular Lymphoma. Clinical Nuclear Medicine, 2022, 47, e47-e48.	0.7	3
115	Ligand engineering for theranostic applications. Current Opinion in Chemical Biology, 2021, 63, 145-151.	2.8	3
116	Internal Radiation Therapy. Recent Results in Cancer Research, 2020, 216, 881-902.	1.8	3
117	A Role of Non-FDG Tracers in Lung Cancer?. Seminars in Nuclear Medicine, 2022, 52, 720-733.	2.5	3
118	Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.. Journal of Clinical Oncology, 2017, 35, 155-155.	0.8	2
119	Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, 5548-5548.	0.8	1
120	Aktuelle radiopharmazeutische Entwicklungen für die theranostische Anwendung. Radiopraxis, 2021, 14, E83-E98.	0.0	0